Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orca-Q in Pediatric Hematopoietic Cell Transplant Recipients With Hematologic Malignancies
NCT05322850Phase 2Recruiting
- Sponsor
- University of Florida
- Start
- Aug 2022
- Primary completion
- Sep 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Orca-Q in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL), acute undifferentiated leukemia (AUL), chronic myeloid leukemia (CML), sponsored by University of Florida. Started Aug 2022; status: recruiting.
02
Drugs
Orca-Q
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)acute undifferentiated leukemia (AUL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05322850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322850.